

HHS Public Access

Author manuscript *Nat Genet.* Author manuscript; available in PMC 2011 January 01.

Published in final edited form as:

Nat Genet. 2010 July ; 42(7): 576-578. doi:10.1038/ng.602.

Common variants in *FOXP1* are associated with generalized vitiligo

Ying Jin^{1,2}, Stanca A. Birlea^{1,3}, Pamela R. Fain^{1,2,4}, Christina M. Mailloux¹, Sheri L. Riccardi¹, Katherine Gowan¹, Paulene J. Holland¹, Dorothy C. Bennett⁵, Margaret R. Wallace⁶, Wayne T. McCormack⁷, E. Helen Kemp⁸, David J. Gawkrodger⁹, Anthony P. Weetman⁸, Mauro Picardo¹⁰, Giovanni Leone¹⁰, Alain Taïeb¹¹, Thomas Jouary¹¹, Khaled Ezzedine¹¹, Nanny van Geel¹², Jo Lambert¹², Andreas Overbeck¹³, and Richard A. Spritz^{1,2} ¹Human Medical Genetics Program, University of Colorado Denver School of Medicine, Aurora, Colorado 80045 USA

²Department of Pediatrics, University of Colorado Denver School of Medicine, Aurora, Colorado 80045 USA

³Department of Dermatology, University of Colorado Denver School of Medicine, Aurora, Colorado 80045 USA

⁴Barbara Davis Center for Childhood Diabetes, University of Colorado Denver School of Medicine, Aurora, Colorado 80045 USA

⁵Division of Basic Medical Sciences, St George's, University of London, London SW17 0RE, United Kingdom

⁶Department of Molecular Genetics & Microbiology, University of Florida College of Medicine, Gainesville, Florida 32610 USA

⁷Department of Pathology, Immunology, & Laboratory Medicine, University of Florida College of Medicine, Gainesville, Florida 32610 USA

⁸Department of Human Metabolism, School of Medicine, University of Sheffield

⁹Department of Dermatology, Royal Hallamshire Hospital, Sheffield S10 2JF, United Kingdom

¹⁰Laboratorio Fisiopatologia Cutanea, Istituto Dermatologico San Gallicano, 00153 Rome, Italy

Author Manuscript

COMPETING INTERESTS STATEMENT

The authors declare no competing financial interests.

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms Correspondence should be addressed to R.A.S. (richard.spritz@ucdenver.edu).

METHODS

Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/. AUTHOR CONTRIBUTIONS

Y.J. performed statistical analyses. K.G. managed computer databases and genotype data. S.L.R. and C.M.M. managed DNA samples and contributed to experimental procedures. P.J.H. managed subject coordination. S.A.B., D.C.B., M.R.W., W.T.M., E.H.K., D.J.G., A.P.W., M.P., G.L., A.T., T.J., K.E., N.VG., J.L., and A.O. provided subject samples and phenotype information. P.R.F. and R.A.S. oversaw and managed all aspects of the study. R.A.S. wrote the first draft of the manuscript. All authors contributed to the final paper.

¹¹Centre de Référence des maladies rares de la peau, Department of Dermatology, Hôpital St-André, 33075 Bordeaux, France

¹²Department of Dermatology, Ghent University Hospital, 9000 Ghent, Belgium

¹³Lumiderm, 28015 Madrid, Spain

Abstract

In a recent genome-wide association study of generalized vitiligo (GV) we identified 10 confirmed susceptibility loci. By testing additional loci that showed suggestive association in the genome-wide study, using two replication cohorts of European descent, we observed replicated association of GV with variants at 3p13 encompassing *FOXP1* (rs17008723, combined $P = 1.04 \times 10^{-8}$) and with variants at 6q27 encompassing *CCR6* (rs6902119, combined $P = 3.94 \times 10^{-7}$).

Generalized vitiligo (GV) is a common, complex autoimmune disease in which patchy depigmentation of skin and hair results from loss of melanocytes from involved areas¹, and which is epidemiologically associated with several other autoimmune diseases². A number of potentially contributory genes have been suggested for GV on the basis of candidate gene association and genetic linkage studies, though few of these have received consistent support³.

We recently carried out a genome-wide association (GWA) study of GV patients and families of European descent, identifying 10 different loci that contribute to GV risk⁴. In addition, seven other loci showed suggestive association with GV in the initial GWA analysis (Supplementary Table 1), defined as nominal P values $< 10^{-4}$ for multiple SNPs clustered across a contiguous genomic region. At 3p13, we observed suggestive association of 9 SNPs spanning nt 71,505,650-71,571,667; most significant was rs17008713 ($P = 3.70 \times$ 10^{-6} , OR = 1.32), located within *FOXP1* (Figure 1a). At 3q13.13, we observed suggestive association of 15 SNPs spanning nt 107,078,487-108,580,778; most significant was rs2603127 ($P = 2.69 \times 10^{-7}$, OR = 1.34), located within *MYH15*. At 6q27 we observed suggestive association of 17 SNPs spanning nt 166,054,922-167814784; most significant was rs6902119 ($P = 5.72 \times 10^{-5}$, OR = 1.21), upstream of CCR6 (Figure 1b). At 7p21.3 we observed suggestive association of three SNPs spanning nt 8,176,301-8,185,089; most significant was rs2192346 ($P = 6.59 \times 10^{-5}$, OR 1.26), located within ICA1. At 9q22.33 we observed suggestive association of 10 SNPs spanning nt100,951,838-101,049,252; most significant was rs7868451 ($P = 8.37 \times 10^{-5}$, OR = 1.22), located within *TBC1D2*. At 12q13.2 we observed suggestive association of 6 SNPs spanning nt 56,368,078-56,491,880; most significant was rs1701704 ($P = 1.66 \times 10^{-7}$, OR = 1.30), located upstream of *IKZF4*. At 12q24.12 we observed suggestive association of 18 SNPs spanning nt 110,557,312-113,039,943; most significant was rs3184504 ($P = 6.91 \times 10^{-6}$, OR = 1.24), located within SH2B3.

To test replication of association of these seven candidate signals, we genotyped the most significant SNP in each locus (Supplementary Table 2) in two independent replication cohorts of European descent: Replication 1 consisted of 647 unrelated GV cases and 1056 non-GV controls (principally spouses of GV cases) and Replication 2 consisted of 183

simplex GV trios and 332 GV multiplex families. SNP rs17008713 could not be genotyped for technical reasons; accordingly, we imputed genotypes for nearby SNP rs17008723 (imputed genotype $r^2 = 0.995$), which is in almost complete LD with rs17008713 in the GWA dataset ($r^2 = 0.99$), and in the replication study we therefore genotyped SNP rs17008723. SH2B3 region SNP rs3184504 and IKZF4 region SNP rs1701704 deviated significantly from Hardy-Weinberg equilibrium in the Replication 1 controls; therefore, these SNPs were excluded from further analysis. Case-control association statistics were calculated using the Cochran-Armitage trend test implemented in PLINK⁵ and family-based association statistics were calculated using FBAT⁶. We carried out a combined metaanalysis of the two replication studies using a Cochran-Mantel-Haenszel test with cases and controls from Replication 1, and cases and pseudocontrols derived from Replication 2, and an overall combined meta-analysis of the two replication studies plus the GWA study. We considered as conservative joint criteria for confirmed association: 1) identification of the same high-risk allele in the GWA study and both of the replication studies; 2) nominally significant (P < 0.05) association in both replication cohorts or significant association in one and marginal association in the other replication cohort; 3) significant (Bonferroni uncorrected $P < 1.0 \times 10^{-2}$; 0.05 / 5) combined replication stage 1 + 2 P value; and 4) a genome-wide significant ($P < 5 \times 10^{-8}$) (^{ref. 7}) overall combined P value.

As shown in Table 1, we replicated association for *FOXP1* region SNP rs17008723 (risk allele G; combined replication stage $1 + 2 P = 1.36 \times 10^{-3}$; overall combined $P = 1.04 \times 10^{-8}$, OR = 1.33; Figure 1a) and for *CCR6* upstream SNP rs6902119 (risk allele C; combined replication $P = 3.79 \times 10^{-3}$; overall combined $P = 3.94 \times 10^{-7}$, OR = 1.23; Figure 1b), although the latter did not achieve the genome-wide significance threshold in the combined analysis. *MYH15* SNP rs2603127 showed a consistent high-risk allele across the three study cohorts, and near genome-wide significant association in the combined analysis ($P = 5.36 \times 10^{-8}$), but showed marginal or no association in the replication cohorts and marginal combined replication *P* values and so was considered unconfirmed. SNPs at two loci, *ICA1* and *TBC1D2*, failed to even show consistent high-risk alleles across the three study cohorts and thus are considered most likely excluded.

FOXP3 and *CCR6* both encode proteins that play important roles in immune regulation. *FOXP1* encodes a widely expressed transcription factor that is essential for the development of B-cells⁸, quiescent naïve T-cells⁹, and monocytes¹⁰, and is paralogous to *FOXP3*, which encodes a transcriptional regulator of regulatory T-cell development and function and is the defective gene in the IPEX multiple autoimmune disease syndrome¹¹. *Foxp1* conditional knock-out mice have premature cell-autonomous hyper-activation of early thymocytes to CD4+ and CD8+ mature T-cells with effector functions⁹.

CCR6 encodes a receptor for macrophage inflammatory protein-3a (CCL20) expressed on unactivated memory B- and T-cells, T-helper 17 cells, and some dendritic cells, and plays a key role in B-cell differentiation and tissue specific migration of dendritic and T cells during inflammatory and immunological responses¹². Another *CCR6* SNP, rs2301436, has been associated with inflammatory bowel disease¹³, with the same high-risk allele observed in the GV GWA dataset ($P = 2.27 \times 10^{-4}$). SNPs rs6902119 and rs2301436 are in moderate LD (r² = 0.64), and logistic regression analysis indicated that association of GV with rs2301436

might be secondary to LD with rs6902119 (P = 0.0712). Recently, we described a small GWA study of GV in an isolated Romanian founder population¹⁴, identifying association in that group with another SNP in 6q27, rs13208776, located 1.44 Mb distal to rs6902119, within *SMOC2*. We find no association between GV and SNPs in the vicinity of rs13208776 in the present study, and no apparent long-range LD between rs6902119 and rs13208776 ($r^2 = 0$); nevertheless, we cannot exclude the possibility that in the Romanian founder population a variant near rs13208776 might influence expression of *CCR6* at a distance. Interestingly, these vitiligo-associated 6q27 SNPs are in close proximity to *IDDM8* (http://www.t1dbase.org), a locus with linkage and association with type I diabetes¹⁵-¹⁸ and rheumatoid arthritis¹⁹, autoimmune diseases that are epidemiologically associated with GV².

Our findings provide additional evidence that variation in genes encoding proteins with roles in the immune system contribute to susceptibility towards GV. Moreover, many of these genes also contribute to other autoimmune diseases, particularly those with which GV is epidemiologically associated. While each of the GV susceptibility loci thus far identified accounts for only a small increase in relative risk, the biological pathways they highlight provide insights into the pathogenesis of GV and other autoimmune diseases, and may afford relatively tractable targets for therapeutic intervention.

Supplementary Material


Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the membership of Vitiligo Support International, the Vitiligo Society, the National Vitiligo Foundation, the American Vitiligo Research Foundation, and Associazione Ricerca Informazione per la Vitiligine for their enthusiastic participation. Supported by grants AR45584 and AR056292 from the National Institutes of Health.

References

- 1. Picardo, M.; Taïeb, A., editors. Vitiligo. Springer; Heidelberg & New York: 2010.
- 2. Alkhateeb A, et al. Pigment Cell Res. 2003; 16:208-214. [PubMed: 12753387]
- 3. Spritz RA. The genetics of generalized vitiligo. Curr Dir Autoimmun. 2008; 10:244–257. [PubMed: 18460890]
- 4. Jin Y, et al. New Engl J Med. Apr 21.2010 Epub ahead of print 2010. [PubMed: 20410501]
- 5. Purcell S, et al. Am J Hum Genet. 2008; 81:559–775. [PubMed: 17701901]
- 6. Horvath S, et al. Genet Epidemiol. 2004; 26:61–69. [PubMed: 14691957]
- 7. The Wellcome Trust Case Control Consortium. Nature. 2007; 447:661-678. [PubMed: 17554300]
- 8. Hu H, et al. Nat Immunol. 2006; 7:819-826. [PubMed: 16819554]
- 9. Feng X, et al. Blood. 2010; 115:510-518. [PubMed: 19965654]
- 10. Shi C, et al. Blood. 2008; 112:4699-4711. [PubMed: 18799727]
- 11. Ochs HD, Gambineri E, Torgerson TR. Immunol Res. 2007; 38:112-121. [PubMed: 17917016]
- 12. Salazar-Gonzalez RM, et al. Immunity. 2006; 24:623-632. [PubMed: 16713979]
- 13. Barrett JC, et al. Nat Genet. 2008; 40:955-962. [PubMed: 18587394]
- Birlea SA, Gowan K, Fain PR, Spritz RA. J Invest Dermatol. 2010; 130:798–803. [PubMed: 19890347]
- 15. Luo DF, et al. Am J Hum Genet. 1995; 57:911–919. [PubMed: 7573053]






Figure 1.

Newly replicated associations in GV. Upper panel shows genomic control-corrected PLINK association results from the GWA scan for genotyped (black) and imputed (blue) SNPs on the y axis versus chromosomal nucleotide position (GRCh37) on the x axis surrounding (**a**) *FOXP1* and (**b**) *CCR6*. Red squares indicate Cochran-Mantel-Haenszel combined *P*-values for the most strongly associated SNP in each locus. LD patterns for SNPs across the regions are shown below. Arrows indicate gene positions and transcriptional orientation. Lower

Page 7

panel shows pairwise r^2 values for LD; darker boxes indicate stronger disequilibrium for SNPs in the upper panel.

SNP Risk allele $\overline{\mathbf{F}_{\mathbf{R}A}, \operatorname{cases}}$ $\overline{\mathbf{F}_{\mathbf{R}A}, \operatorname{cases}}$ $\overline{\mathbf{F}_{\mathbf{R}A}, \operatorname{cases}}$ $\overline{\mathbf{P}_{\mathbf{R}A}, \operatorname{cases}}$ $\overline{\mathbf{P}_{\mathbf{R}A}, \operatorname{cases}}$ $\overline{\mathbf{P}_{\mathbf{R}A}, \operatorname{cases}}$ $\overline{\mathbf{O}}$ $\overline{\mathbf{P}}$ $\overline{\mathbf{O}}$ $\overline{\mathbf{O}}$ $\overline{\mathbf{O}}$ $\overline{\mathbf{O}$ $\overline{\mathbf{O}}$ \overline	SNP Risk allele AF_{RA} , cases AF_{RA} , con Replicated 0.171 171008723 0.214 0.171 rs17008723 G 0.214 0.171 rs6902119 C 0.495 0.446 Uncertain 0.247 0.213 rs2603127 A 0.247 0.213 SNPs rs17008723, rs2603127, and rs6902119 were locate respectively. SNP nucleotide positions are from GRCh37 SNPs rs17008723, rs6902119, and rs2603127 were 6.25 inflation factor 1.048 as described in the Supplementary here	GWA Study		Replication 1	1	Replication 2	tion 2	Meta-analysis Replication 1 + Replication 2	plication 1 + on 2	Meta-analysis GWA + Replication 1 + Replication 2	+ Replication tion 2
Replicated rs17008723 G 0.214 0.171 3.65×10^{-6} 1.32 1.47×10^{-3} 1.35 0.017 1.26 1.36×10^{-3} 1.36×10^{-8} 1.33 rs6902119 C 0.495 0.446 5.72×10^{-5} 1.21 2.92×10^{-3} 1.28 0.058 1.09 3.79×10^{-3} 1.25 3.94×10^{-7} 1.23 Uncertain rs2603127 A 0.247 0.213 2.69×10^{-7} 1.34 0.078 1.00 0.085 1.19 5.36×10^{-8} 1.30 SNPs rs17008723, rs2603127, and rs6902119 were located at nt 71,573,135 in the <i>FOXPI</i> region of 3p13; nt 167,505,791 in the <i>CCR6</i> region of 6q27; and nt 108,243,551 in the <i>MYH15</i> region of 3q13.13, rescentively continue are from GPCH27 and cancel in close movinity to the desimated SNP are denoted AED 2, and remain to the desimated SNP are denoted AED 2, and remain to the desimated SNP are denoted AED 2, and remain to the desimated SNP are denoted AED 2, and remain to the desimated SNP are denoted AED 2, and remain to the desimated SNP are denoted AED 2, and remain to the desimated SNP are denoted AED 2, and remain to the desimated SNP are denoted AED 2, and remain to the desimated SNP are denoted AED 2, and remain to the desimated SNP are denoted AED 2, and remain to the desimated SNP are denoted AED 2, and remain to the desimated SNP are denoted AED 2, and remain to the desimated SNP are denot	Replicated 0.214 0.171 rs17008723 G 0.214 0.171 rs6902119 C 0.495 0.446 Uncertain 0.247 0.213 rs2603127 A 0.247 0.213 SNPs rs17008723, rs2603127, and rs6902119 were locate respectively. SNP nucleotide positions are from GRCh37 SNPs rs17008723, rs6902119, and rs2603127 were 6.25 > inflation factor 1.048 as described in the Supplementary h		OR	ď	OR	Ρ	OR	Ρ	OR	Ρ	OR
rs 17008723 G 0.214 0.171 3.65 × 10 ⁻⁶ 1.32 1.47 × 10 ⁻³ 1.35 0.017 1.26 1.36 × 10 ⁻³ 1.36 1.04 × 10 ⁻⁸ 1.33 rs 6902119 C 0.495 0.446 5.72 × 10 ⁻⁵ 1.21 2.92 × 10 ⁻³ 1.28 0.058 1.09 3.79 × 10 ⁻³ 1.25 3.94 × 10 ⁻⁷ 1.23 Uncertain rs 2602119 C 0.495 0.446 5.72 × 10 ⁻⁵ 1.21 2.92 × 10 ⁻³ 1.28 0.058 1.09 3.79 × 10 ⁻³ 1.25 3.94 × 10 ⁻⁷ 1.23 Uncertain rs 2603127 A 0.247 0.213 2.69 × 10 ⁻⁷ 1.34 0.404 1.09 0.078 1.00 0.085 1.19 5.36 × 10 ⁻⁸ 1.30 rs 2603127 A 0.247 0.213 2.69 × 10 ⁻⁷ 1.34 0.404 1.09 0.078 1.00 0.085 1.19 5.36 × 10 ⁻⁸ 1.30 rs 2603127, and rs 6902119 were located at nt 71,573,135 in the <i>FOXPI</i> region of 3p13; nt 167,505,791 in the <i>CCR</i> 6 region of 6q27; and nt 108,243,551 in the <i>MYH15</i> region of 3q13.13, reservicing to the maximic to the descimated SND are denoted AFD to a denoted AFD to a label feature of the risk of label FIGFNSTE AT CRM. A robust for the risk of label feature of the risk of label FIGFNSTE AT CRM. A robust for the risk of label feature of the risk of label feature of the risk of label FIGFNSTE AT CRM. A robust for the rest of the rest of the risk of label FIGFNSTE AT CRM. A robust for the risk of label feature of the risk of the risk of label feature of the risk of risk of label feature of the risk of	rs17008723 G 0.214 0.171 rs6902119 C 0.495 0.446 Uncertain 0.247 0.213 rs2603127 A 0.247 0.213 SNPs rs17008723, rs2603127, and rs6902119 were locate respectively. SNP nucleotide positions are from GRCh37 SNPs rs17008723, rs6902119, and rs2603127 were 6.25 > SNPs rs17008723, rs6902119, and rs2603127 were 6.25 > inflation factor 1.048 as described in the Supplementary N										
rs6902119 C 0.495 0.446 5.72×10^{-5} 1.21 2.92×10^{-3} 1.28 0.058 1.09 3.79×10^{-3} 1.25 3.94×10^{-7} 1.23 Uncertain rs2603127 A 0.247 0.213 2.69×10^{-7} 1.34 0.078 1.00 0.085 1.19 5.36×10^{-8} 1.30 SNPs rs17008723, rs2603127, and rs6902119 were located at nt 71,573,135 in the <i>FOXPI</i> region of 3p13; nt 167,505,791 in the <i>CCR6</i> region of 6q27; and nt 108,243,551 in the <i>MYH15</i> region of 3q13.13, reservively. SND nucleation suctions are from GPCH77 and ranks in close meriview of the decimated SND are denoted AED. A flab frequency of the risk allal a FIGFNSTP AT GWD. A values for the form of the decimated SND are denoted AED. A flab frequency of the risk allal a FIGFNSTP AT GWD. A values for the form of the decimated SND are denoted AED. A flab frequency of the risk allal a FIGFNSTP AT GWD. A values for the form of the decimated SND are denoted AED. A flab frequency of the risk allal a FIGFNSTP AT GWD. A values for the form of the decimated SND are denoted AED. A flab frequency of the risk allal a FIGFNSTP AT GWD. A values for the form of the decimated SND are denoted AED. A A values for the form of the decimated SND are denoted AED. A values for the form of the decimated SND are denoted AED. A for the decimated SND are formed of the decimated SND are denoted AED. A for the decimated SND are form of the decimated SND are denoted AED. A form of the decimated SND are form of the decimated SND	rs6902119 C 0.495 0.446 Uncertain 0.247 0.213 rs2603127 A 0.247 0.213 SNPs rs17008723, rs2603127, and rs6902119 were locate respectively. SNP nucleotide positions are from GRCh37 SNPs rs17008723, rs6902119, and rs2603127 were 6.25 > SNPs rs17008723, rs6902119, and rs2603127 were 6.25 > inflation factor 1.048 as described in the Supplementary N		1.32	1.47×10^{-3}	1.35	0.017	1.26	$1.36 imes 10^{-3}$	1.36	$1.04 imes 10^{-8}$	1.33
Uncertain rs2603127 A 0.247 0.213 2.69×10^{-7} 1.34 0.404 1.09 0.078 1.00 0.085 1.19 5.36×10^{-8} 1.30 SNPs rs17008723, rs2603127, and rs6902119 were located at nt 71,573,135 in the <i>FOXP1</i> region of 3p13; nt 167,505,791 in the <i>CCR6</i> region of 6q27; and nt 108,243,551 in the <i>MYH15</i> region of 3q13.13, reservively CNP and ensering characterized with the design of APD as all all fermions of the risk of label FIGFNOTP AT GWA <i>P</i> , volues for the second characterized of the region of 6q27; and nt 108,243,551 in the <i>MYH15</i> region of 3q13.13, reservively CNP and reservively to the design of APD as all all fermions of the risk of label FIGFNOTP AT GWA <i>P</i> , volues for the region of 3p13.13, reservively CNP and reservively to the design of APD as all all fermions of the risk of label FIGFNOTP AT GWA <i>P</i> , volues for the form the form of the region of 3p13, nt 167, 505, 791 in the CCR6 region of 6q27; and nt 108, 243, 551 in the <i>MYH15</i> region of 3q13.13, reservively to the design and a transformed and the reservively to the design and the former of the risk of all a FIGFNOTP AT GWA <i>P</i> , volues for the form the form the form of the reservively to the design and the former of the risk of all a FIGFNOTP AT GWA <i>P</i> , volues for the form the form of the risk of all all fermions of the risk of all all a FIGFNOTP AT GWA <i>P</i> , volues for the risk of the former of the risk of all all reserves former former of the risk of all all reserves former former of the risk of all all reserves former	Uncertain rs2603127 A 0.247 0.213 SNPs rs17008723, rs2603127, and rs6902119 were locate respectively. SNP nucleotide positions are from GRCh37 SNPs rs17008723, rs6902119, and rs2603127 were 6.25 > inflation factor 1.048 as described in the Supplementary N					0.058	1.09	$3.79 imes 10^{-3}$	1.25	$3.94 imes 10^{-7}$	1.23
rs2603127 A 0.247 0.213 2.69×10^{-7} 1.34 0.404 1.09 0.078 1.00 0.085 1.19 5.36×10^{-8} 1.30 SNPs rs17008723, rs2603127, and rs6902119 were located at nt 71,573,135 in the <i>FOXP1</i> region of 3p13; nt 167,505,791 in the <i>CCR6</i> region of 6q27; and nt 108,243,551 in the <i>MYH15</i> region of 3q13.13, respectively. SND nucleations are from GPCF47 and ranse in close previously to the destination of AFD A and labele framework the risk allele framework the risk allele FIGFNSTP AT GWA A values for	rs2603127A0.2470.213SNPs rs17008723, rs2603127, and rs6902119 were locate respectively. SNP nucleotide positions are from GRCh37SNPs rs17008723, rs6902119, and rs2603127 were 6.25 >inflation factor 1.048 as described in the Supplementary A										
SNPs rs17008723, rs2603127, and rs6902119 were located at nt 71,573,135 in the <i>FOXP1</i> region of 3p13; nt 167,505,791 in the <i>CCR6</i> region of 6q27; and nt 108,243,551 in the <i>MYH15</i> region of 3q13.13, researchiely. SNP nucleatide maximum careform are from GRCh37 and cames in close maximity to the designated SND are denoted. AFD A. allele featurement of the risk allele. FIGFNSTR AT GWA <i>P</i> , volues for	SNPs rs17008723, rs2603127, and rs6902119 were locate respectively. SNP nucleotide positions are from GRCh37 SNPs rs17008723, rs6902119, and rs2603127 were 6.25 > inflation factor 1.048 as described in the Supplementary N		1.34		60.1	0.078	1.00	0.085	1.19	$5.36 imes 10^{-8}$	1.30
	SNPs rs17008723, rs6902119, and rs2603127 were 6.25 × inflation factor 1.048 as described in the Supplementary A	ed at nt 71,573,135 in 7 and genes in close pro	the <i>FOX</i>	<i>P1</i> region of 3p	13; nt 1 1 SNP a	67,505,	791 in the ted AFD	e <i>CCR6</i> region of 6q2	27; and nt 108,2. of the risk allele	43,551 in the <i>MYH15</i> re FIGENSTR AT GWA <i>I</i>	gion of 3q13.13, -values for
		Methods. The Bonferr	oni adjus	ited significance	thresh	old for th	he combi	ined replication stage	1 + 2 meta-anal	vsis was $P < 1.00 \times 10^{-1}$	2, and the
inflation factor 1.048 as described in the Supplementary Methods. The Bonferroni adjusted significance threshold for the combined replication stage $1 + 2$ meta-analysis was $P < 1.00 \times 10^{-2}$, and the	significance threshold for the overall combined $GWA + \pi c$ study for technical reasons: therefore, genotypes for nearb	replication stage 1 + 2 bv SNP rs17008723 (r	meta-an: 2 = 0.99	alysis was $P < 5$	5×10^{-8} and $rs1$	S. FOXP	1 SNP rs 3 was ge	.17008713 from the C notyped in the replice	WA study could ation study. Data	d not be genotyped in th a for SNPs rs2192346 ar	e replication id rs7868451. for
inflation factor 1.048 as described in the Supplementary Methods. The Bonferroni adjusted significance threshold for the combined replication stage $1 + 2$ meta-analysis was $P < 1.00 \times 10^{-2}$, and the significance threshold for the combined replication stage $1 + 2$ meta-analysis was $P < 1.00 \times 10^{-2}$, and the significance threshold for the combined replication stage $1 + 2$ meta-analysis was $P < 1.00 \times 10^{-2}$, and the significance threshold for the combined replication stage $1 + 2$ meta-analysis was $P < 1.00 \times 10^{-2}$, and the significance threshold for the overall combined GWA + replication stage $1 + 2$ meta-analysis was $P < 5 \times 10^{-8}$. Fo <i>XPI</i> SNP rs17008713 from the GWA study could not be genotyped in the replication study. Data for SNPs rs2192346 and rs7868451, for study for technical reasons; therefore, genotypes for nearby SNP rs17008723 ($r^2 = 0.99$) were imputed, and rs17008723 was genotyped in the replication study. Data for SNPs rs2192346 and rs7868451, for	which association was excluded, are shown in Supplementary Table 3.	ntary Table 3.		•)	:	•		

Author Manuscript

Author Manuscript